CPHI is one of the places where the pharmaceutical industry makes its transformations visible. Not only through new technologies and manufacturing capabilities, but also through the way development, manufacturing, outsourcing, supply chain and quality are increasingly integrated into complex industrial architectures.
For pharma, this evolution is particularly evident in its relationship with CDMOs. Their role is expanding: manufacturing capacity is now complemented by specialist expertise, development support, technology transfer, risk management, supply chain resilience and the ability to support increasingly complex products throughout their lifecycle. Choosing an industrial partner is therefore no longer simply a matter of availability, timelines and cost, but of how effectively infrastructure, people, technologies and quality systems can work together.
This MakingPharmaIndustry Magazine – Special CPHI October 2026 was created to explore precisely this transformation, broadening the perspective from outsourcing to the conditions required to make pharmaceutical manufacturing robust, flexible and adaptable.
The issue examines some of the key areas that are reshaping pharma’s industrial infrastructure: the evolution of the CDMO model, the relationship between manufacturing capacity and expertise, the choice between integrated and specialist providers, the role of cleanrooms and contamination control strategies, facility design, energy efficiency, the resilience of global supply chains, as well as particle control technologies and packaging.
What emerges is an industry in which competitiveness no longer depends on a single asset or technology, but on the ability to manage increasingly close connections between development, manufacturing, quality, infrastructure and supply networks.
Explore the MakingPharmaIndustry Magazine – Special CPHI October 2026.
Vuoi trovare più facilmente MakingPharmaIndustry su Google?
Aggiungici alle tue fonti preferite
